The list below includes links to all abstracts accepted as Oral Presentations, Posters, or for Online-Publication-Only. 

Oral Presentations and Posters are available to registered attendees only via the ASH annual meeting virtual platform, as per congress regulations.

Medical materials

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Emapalumab induces rapid, durable responses and reliable bridging to curative HSCT in patients with primary HLH: Pooled analysis of prospective trials NI-0501-04, NI-0501-05 and NI-0501-09

Michael B. Jordan, Franco Locatelli, Didier Halimi, Elena Burillo, Brian D. Jamieson, Andrew Danquah, Emmanuel Monnet

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib: The MY-PAC Study

Douglas Tremblay, Abiola Oladapo, Michael Marrone, Puja Aggarwal, Caleb Paydar, Djibril Liassou, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg, James Rossetti, Naveen Pemmaraju

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Incidence, prevalence, and clinical outcomes of myelofibrosis with and without cytopenia in the United States

Aaron T Gerds, Lindsay AM Rein, Nicole M Engel-Nitz, Michael Marrone, Jeffrey McPheeters, Abiola Oladapo, Purvi Suthar, Michael Vredenburg , Yong Zhu, Lucia Masarova

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Quality of life and functional improvements with efanesoctocog alfa in patients with moderate to severe hemophilia A: A real-world survey 

Maissaa Janbain, Miguel A. Escobar, Manuel Carcao , Nathan Ball, Ella Morton, Duygu Bozkaya, Sylvie Bozzi, Nicole Tsao, Andrew Wilson

Publication
  • ASH •
  • 8 December, 2025 •
  • •

Patient-reported outcomes of avatrombopag for chronic immune thrombocytopenia: Interim analysis of the Phase 4 adopt study

María Eva Mingot Castellano, María Teresa Álvarez Román, María Luisa Lozano, Wolfgang Miesbach, Hafiz Qureshi, Vickie McDonald, Jessica Zhang, Viridiana Cano Garcia, Nina Skuban

Publication
  • ASH •
  • 7 December, 2025 •
  • •

Use of Emapalumab is associated with Rapid and Sustained Benefits in pHLH Subgroups, Including CNS Involvement and Previously Untreated Patients: Pooled analysis of prospective trials NI-0501-04, NI-050105 and NI-050109

Franco Locatelli, Michael B. Jordan, Didier Halimi, Elena Burillo, Brian D. Jamieson, Emmanuel Monnet, Andrew Danquah

Publication
  • ASH •
  • 7 December, 2025 •
  • •

Real-world treatment patterns and outcomes in patients with myelofibrosis who presented with thrombocytopenia and anemia at initiation of pacritinib treatment

Naveen Pemmaraju, Abiola Oladapo, Michael Marrone, Puja Aggarwal, Caleb Paydar, Djibril Liassou, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg, James Rossetti, Douglas Tremblay

Publication
  • ASH •
  • 7 December, 2025 •
  • •

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC): Results from the MY-PAC Study

Douglas Tremblay, Abiola Oladapo, Michael Marrone, Puja Aggarwal, Caleb Paydar, Djibril Liassou, Purvi Suthar, Adina Geprifti, Gerard Hoehn, Michael Vredenburg , Bruce Feinberg, Naveen Pemmaraju, James Rossetti

Publication
  • ASH •
  • 7 December, 2025 •
  • •

PROSPERA (ABNL-MARRO 002): A Randomized Phase 2 Study of Pacritinib vs. Hydroxyurea in Patients with Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)

Zhouer Xie, Qianxing Mo, Sarah Buckley, David Sallman, Jeffrey Lancet, Michael Savona, Rami Komrokji, Mrinal Patnaik, Daniel Wiseman, Eric Padron

Publication
  • ASH •
  • 7 December, 2025 •
  • •

Clinical Outcomes up to 4 Years of Once-Weekly Efanesoctocog Alfa Prophylaxis in Previously Treated Adults, Adolescents, and Children with Severe Hemophilia A: Interim Analysis of the Phase 3 XTEND-ed Long-Term Extension Study 

Sophie Susen, Anthony KC Chan, Pratima Chowdary, Stephanie P’ng, Manuela Albisetti, Keiji Nogami, Karin Fijnvandraat, Jennifer Dumont, Elena Santagostino, Sriya Gunawardena, Mahnouch Georget, Lynn Malec

Publication
  • ASH •
  • 6 December, 2025 •
  • •

Pacritinib in patients with high-risk myelofibrosis: outcomes from post-hoc analyses of two Phase 3 studies

Pankit Vachhani, Nikolai Podoltsev, Ashwin Kishtagari, Purvi Suthar, Michael Vredenburg , Karisse Roman-Torres, Aaron Gerds

Publication
  • ASH •
  • 6 December, 2025 •
  • •

Understanding Unmet Needs for People with Haemophilia A Receiving Factor and Non-Factor Treatments 

Nana Kragh, Veruska Carboni, Duygu Bozkaya, Idaira Rodriguez-Santana, Claudia Mighiu, Bethany Franks, Arnoud Plat, Randall Curtis 

Publication
  • ASH •
  • 6 December, 2025 •
  • •

Real-world Experience of Efanesoctocog Alfa in Hemophilia A Patients in the US: A Retrospective Analysis 

Sibgha Zaheer, Nina Hwang, Kyle Davis, Erin Cockrell, Andrew Wilson, Ana Rita Delgado, Jennifer Dumont , Nicole Tsao

Publication
  • ASH •
  • 6 December, 2025 •
  • •

Patient characteristics, treatment patterns, and bleeding in people with hemophilia A without inhibitors initiating efanesoctocog alfa in the US: An administrative claims analysis 

Miguel Escobar, Siddhi Umarje, Gandarvaka Miles, Sylvie Bozzi, Andrew Wilson, Jennifer Dumont , Duygu Bozkaya

Publication
  • ASH •
  • 6 December, 2025 •
  • •

Real-world treatment patterns & outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the real-AVA 3.5 study

Caroline Piatek, Abiola Oladapo, Scott Kolodny, Michael Vredenburg , Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Hillary Maitland

Publication
  • ASH •
  • 6 December, 2025 •
  • •

Real-world safety and efficacy of avatrombopag in adults with immune thrombocytopenia: A systematic review and meta-analysis

María Luisa Lozano, David Valcarcel

Sign up for alerts